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Abstract To identify genes whose expression is modulated by
heregulin-L1 (HRG), a regulatory polypeptide for mammary
epithelial cells, we performed di¡erential display screening of
MCF-7 cell mRNA. One cDNA clone upregulated by HRG
was identical to human ADP-ribosylation factor 3 (ARF3), a
guanine nucleotide-binding protein functioning in vesicular traf-
¢cking, phospholipase D activation and intracellular transport.
HRG treatment increased expression of ARF3 mRNA and
protein. Also, HRG triggered a rapid redistribution of ARF3,
¢rst to cell membranes and then to the nuclear compartment,
where ARF3 colocalized with acetylated histone H3 in discrete
regions. In addition, the ARF3 protein was developmentally
regulated in the mammary gland with the highest levels in virgin
and post-weaning glands. Together, these ¢ndings suggest
for the ¢rst time that stimulation of ARF3 expression, subcel-
lular redistribution and interaction with acetylated histone H3
may play a role in the action of HRG in mammary epithelial
cells. 0 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Growth factors and their receptors play an important role
in the regulation of epithelial cell growth. Heregulin-L1
(HRG), a combinatorial ligand for the human epidermal
growth factor receptors (HERs) HER3 and HER4, is a secre-
tory polypeptide that a¡ects growth stimulation, di¡erentia-
tion, invasiveness and motility of breast cancer cells [1^7]. In
mammary epithelial cells, HRG predominantly uses HER3/
HER2 to exact its biological e¡ects [8]. Additionally, HRG
is known to be expressed in the mammary mesenchyme adja-
cent to lobuloalveolar structures and is maximally expressed
during pregnancy [7]. HRG also plays a role in the morpho-
genesis and ductal migration of mammary epithelial cells [2,5],
promotes the responsiveness of these cells to lactogenic hor-
mones in vitro [6] and induces the di¡erentiation of mammary
epithelium into secretory lobuloalveoli [7]. These observations
suggest that HRG is a regulatory polypeptide having distinct
biological e¡ects, such as growth stimulation, di¡erentiation,
invasiveness and migration, in mammary epithelial cells.
ADP-ribosylation factors (ARFs) are members of the Ras
super-family of 20 kDa guanine nucleotide-binding proteins
that were initially discovered by their ability to stimulate the
ADP-ribosyltransferase activity of the cholera toxin A [9].
ARFs regulate exocytic and endocytic vesicular tra⁄cking,
phospholipase D activation, endoplasmic reticulum (ER)
and Golgi morphology and function, ER^Golgi transport
and nuclear membrane fusion [10^13]. Although ARFs follow
a very similar protein folding with that of Ras, they distinctly
di¡er in two structural aspects that are absent in Ras: an
extra L-strand and an N-terminal K-helix [14]. In mammals,
the ARF family consists of six ARFs and about 10 ARF-like
proteins. Both ARFs and ARF-like proteins are highly con-
served molecules [15,16]. The expression of ARFs has been
shown to be tissue-speci¢c and developmentally in£uenced.
For example, ARF3 mRNA increases from 2 to 17 days
post-natally in rat, while mRNAs for other family members
decline or remain unchanged [13]. Among the ARF family
members, ARF-like protein 4 is the only reported member
with nuclear/nucleolar localization [17].
Like other GTPases, inactive ARFs exist as a cytosolic
GDP-bound form and become activated and often mem-
brane-associated when bound with GTP. Since ARFs possess
a low intrinsic GTPase activity, GTPase-activating proteins
are required for ARF function [18]. GTP hydrolysis by
ARF is a prerequisite for vesicle uncoating [18]. The cyclic
nature of activation and de-activation of ARFs is thought
to correspond with its interaction and release from intracellu-
lar membranes [19]. In spite of the widely believed involve-
ment of ARF3 in secretory pathways, very little is known
about its role in the action of growth factors.
Because the diverse functions of HRG are likely dependent
on induced changes in the expression of speci¢c cellular gene
products, we used the di¡erential display of mRNA to iden-
tify HRG-regulated genes in breast cancer cells. Our results
suggest that ARF3 expression and its nuclear translocation
are positively regulated by HRG.
2. Materials and methods
2.1. Cell cultures and reagents
Human breast cancer cell lines were maintained in Dulbecco’s
modi¢ed Eagle’s medium and F12 (1:1) supplemented with 10% fetal
calf serum. Antibodies used were against ARF3 (Transduction Labo-
ratories), acetylated histone H3 (UBI) and the HA (MBL). Actin-
binding phalloidin, £uorescently conjugated second antibodies and
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the DNA-intercalating £uorescent dye ToPro3 were from Molecular
Probes.
2.2. Cell extracts and immunoprecipitation
For the preparation of cell extracts, cells were washed three times
with phosphate-bu¡ered saline (PBS) and lysed in RIPA bu¡er sup-
plemented with 100 mM NaF, 200 mM NaVO5, 1 mM phenylmeth-
ylsulfonyl £uoride, 10 Wg/ml leupeptin and 10 Wg/ml aprotinin on ice
for 15 min. The lysates were then centrifuged in an Eppendorf cen-
trifuge at 4‡C for 30 min. Cell lysates containing equal amounts of
protein were immunoprecipitated with the desired antibody and ana-
lyzed by SDS^PAGE [20^23].
2.3. Di¡erential display analysis
Di¡erential display was performed using MCF-7 with and without
HRG treatment using the Delta Di¡erential Display kit and as pre-
viously described [21,22].
2.4. Northern blot hybridization
Total cytoplasmic RNA was isolated using the Trizol reagent and
20 Wg of RNA analyzed via Northern blot hybridization using a 600
bp cDNA of human ARF3 open reading frame. rRNA (28S and 18S)
was used to assess the integrity of the RNA. The blots were routinely
reprobed with human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA for RNA loading and transfer control. In some
experiments, cells were treated with 50 Wg/ml cycloheximide (a trans-
lational inhibitor) or 10 Wg/ml actinomycin D (a transcriptional in-
hibitor) in the presence or absence of HRG treatment (1 nM). Indi-
vidual bands were quanti¢ed by scanning densitometry and graphed
as the meanQ standard deviation (S.D.) of three experiments.
2.5. Immuno£uorescence and confocal imaging
MCF-7 cells were plated on glass cover slips in six-well culture
plates and transfected with an HA-tagged ARF construct using Fu-
gene 6 (Roche). Subcon£uent cells were serum-starved for 24 h, then
separate wells were treated with HRG (1 nM) for 0, 30 or 60 min or
overnight for 16 h and the cells were rinsed in PBS and ¢xed in 4%
phosphate-bu¡ered formaldehyde for 20 min. Following ¢xation, cells
were processed for immuno£uorescence staining as previously de-
scribed [22]. Fluorescent labeling was visualized using a Zeiss LSM
510 microscope and a 40U objective. Quantitation of two channel
pixel intensity along a ¢xed line (Fig. 3A^C) was performed using
Zeiss LSM 510 image analysis software.
3. Results and discussion
3.1. Identi¢cation of ARF3 as a growth factor-regulated gene
To identify genes whose expression in human breast cancer
cells may be modulated by HRG, we prepared total RNA
from MCF-7 breast cancer cells treated with or without
HRG. Complementary DNAs were synthesized using a re-
verse transcriptase in the presence of [K-32P]dCTP and sub-
jected to a polymerase chain reaction. A total of 90 reactions
were performed using nine 3P-degenerate oligo-dT primers and
ten 5P-random primers for each treatment. Analysis of PAGE
gels showed bands were of equal intensity. Using these bands
as internal controls, we looked for bands having di¡erences in
intensity in the HRG-treated lane. This analysis resulted in
the identi¢cation of a 186 bp band di¡erentially expressed in
HRG-treated cells (Fig. 1A). The di¡erentially expressed gene
product was then ampli¢ed, cloned and sequenced. Five
Fig. 1. Identi¢cation of ARF3 as a di¡erentially expressed gene in HRG-stimulated cells. A: Representative di¡erential display band patterns
of control and HRG (1 nM for 12 h)-treated MCF-7 cells. The arrow indicates the band of interest, which is upregulated by HRG treatment.
B: MCF-7 and BT-474 cells were treated with 1 nM HRG for 8 or 16 h. Total RNA was isolated, and the ARF3 mRNA level was detected
using Northern blot analysis. Subsequently, the blot was reprobed using a GAPDH cDNA probe. The mean (Q S.D.) expression of ARF3
mRNA from three separate experiments was determined by densitometry and is shown in the bottom panel. C: MCF-7 cells were treated with
1 nM HRG for 16 h. Total lysates were run on SDS^PAGE gels and blotted with an anti-ARF3 monoclonal antibody. Anti-vinculin antibody
was used as an internal control. Quantitation of the ratio of ARF3 to vinculin is shown in the bottom panel.
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clones were sequenced and all ¢ve sequences were 100% iden-
tical to human ARF3 from 2721 to 2906 (ARF3 GenBank
accession number BC017565). To determine whether ARF3
mRNA can be modulated by HRG in tumor cells, we per-
formed Northern blot hybridization using the 0.6 kb ARF3
cDNA as a probe. HRG treatment of MCF-7 and BT-474
cells was accompanied by a signi¢cant increase in the ARF3
mRNA level (Fig. 1B). HRG treatment also increased the
level of ARF3 protein in MCF-7 cells (Fig. 1C). Taken to-
gether, these results suggested that HRG upregulates the ex-
pression of ARF3.
3.2. HRG regulates ARF3 at the pretranslational level
The observed HRG-mediated increase in ARF3 mRNA
expression may have been due to increased synthesis of newly
transcribed mRNA, enhanced stability of ARF3 mRNA, or
both. Pretreatment of cells with actinomycin D, an inhibitor
of transcription, abolished the HRG-mediated induction of
ARF3 mRNA expression, suggesting the need for continuous
RNA synthesis in the observed increased expression of ARF3
mRNA in HRG-treated cells (Fig. 2A). Treatment with cyclo-
heximide, a translational inhibitor, had only a marginal e¡ect
on ARF3 mRNA levels (Fig. 2A). We next examined the
status of ARF3 promoter chromatin by CHIP analysis using
antibodies speci¢c for acetylated forms of H3 and H4. There
was a signi¢cant enhancement in the association of acetylated
histone H3 with the ARF3 promoter region in HRG-treated
MCF-7 cells, but not in control serum-starved cells as de-
tected by chromatin immunoprecipitation (data not shown).
This ¢nding provided evidence for open chromatin conforma-
tion at the ARF3 promoter following HRG treatment. These
observations suggested a role of histone H3 in the regulation
of ARF3 promoter following HRG treatment and suggested
that HRG regulated ARF3 expression at a pretranslational
level.
3.3. HRG rapidly redistributes ARF3 in breast cancer cells
Since HRG is known to regulate vesicle tra⁄cking [24], and
ARF3 is involved in exocytosis [25], we next sought to deter-
mine the in£uence of HRG on the subcellular distribution of
ARF3. To visualize the e¡ect of HRG on ARF3 localization,
MCF-7 cells were transiently transfected with a HA-tagged
ARF3 and treated with HRG for various lengths of time,
then HA-ARF3 was localized by immuno£uorescent labeling
and confocal microscopy. In control MCF-7 cells, HA-ARF3
was normally localized within the cell cytoplasm, with some
accumulation around the nuclear membrane (Fig. 3A). After
60 min of HRG treatment, there was a dramatic relocalization
of HA-ARF3 to the nucleus (Fig. 3B). However, after 16 h of
HRG treatment, ARF3 was no longer seen in the nucleus, but
was rather localized in the cytoplasm and at the cell periphery.
These observations suggested that HRG-generated signals
could trigger an early redistribution of ARF3 to the nucleus.
ARF3 has been shown to bind the mitotic kinesin-like protein
1 in a GTP-dependent fashion [26]. Our observations sug-
gested a role for ARFs in protein shuttling into the nucleus,
which could happen as a result of signaling with a cellular
growth factor such as HRG. However, no nuclear localization
and/or function for ARF3 has previously been reported.
3.4. ARF3 colocalizes with acetylated histone H3
Since HRG induced rapid ARF3 movement into the nu-
cleus, we wanted to determine if ARF3 might be involved
with the chromatin remodeling induced by HRG. MCF-7 cells
were again transfected with HA-ARF3, serum-starved for 24 h
and then treated with 1 nM HRG for either 30 or 60 min.
Immuno£uorescence and confocal microscopy again showed
the rapid relocalization of ARF3, ¢rst to the cell membrane
(Fig. 3E) and then to the nucleus (Fig. 3F). Acetylated histone
H3 was virtually absent in serum-starved cells (Fig. 3D), but
also rapidly increased with HRG treatment. Interestingly,
ARF3 and acetylated histone H3 colocalized to speci¢c spots
around the nucleoli after 60 min of HRG treatment (Fig. 3F).
This is the ¢rst report of speci¢c nuclear localization of ARF3
following growth factor signaling and the ¢rst report of colo-
calization of ARF3 with acetylated histone H3. Thus ARF3
may be an e¡ector protein for growth factor-induced changes
in gene expression.
3.5. ARF3 expression in mammary epithelial cells
Growth factors and their receptors play a critical role in
epithelial cancer promotion and progression. We next ex-
plored whether there is any relationship between the levels
of ARF3 and tumorigenic potential of breast cancer cell lines.
Results in Fig. 4A show that ARF3 is an abundantly ex-
pressed protein in most of the cell lines used here. There
was no correlation between the level of ARF3 and overexpres-
sion of the HER2 receptor, as HER2 overexpressing SKBR3
and BT-474 cells exhibited varied levels of ARF3 and low
HER2 expressing MCF-7 cells had a higher ARF3 content
than SKBR3 cells. We next determined the expression pro¢le
of ARF3 in various murine organs and the di¡erent stages of
mammary gland development. Higher levels of ARF3 protein
were detected in ovary and uterus, and protein levels were
extremely low in testis, brain, lung, and adrenal and thyroid
glands (Fig. 4B). Interestingly, in the mammary gland, the
ARF3 protein expression was developmentally regulated
with the highest levels in virgin and post-weaning glands
Fig. 2. HRG induces ARF3 mRNA expression in the absence of de
novo protein synthesis. MCF-7 cells were treated with cycloheximide
(50 Wg/ml) or actinomycin D (10 Wg/ml) in the presence or absence
of HRG (1 nM). Total RNA was isolated and the level of ARF3
mRNA was detected using Northern blotting. The mean (QS.D.)
expression of ARF3 mRNA from three separate experiments was
determined by densitometry and is shown in the bottom panel.
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and its levels were signi¢cantly reduced during lactation and
early post-weaning stages of mammary gland development
(Fig. 4C). Since ARF3 expression was highest during the
late post-weaning stage characterized by remodeling and
also in virgin mammary gland, these observations suggest a
physiological role of ARF3 in the mammary gland.
In summary, we have presented new evidence that growth
factor stimulation of breast cancer cells signi¢cantly increases
the expression of ARF3. Since the level of baseline ARF3
expression did not correlate well with the HER2 overexpres-
sion in di¡erent cell lines, ligand-activated cellular pathways,
rather than receptor levels, may be important in the regulation
of ARF3 expression. In addition, we have also provided new
evidence in support of growth factor-triggered rapid nuclear
redistribution of ARF3, implying a putative role of ARF3 in
modulating nuclear functions and/or gene expression in
growth factor-activated cells. Consistent with such a possibil-
ity, we noticed a temporal relationship between the kinetics of
the nuclear presence of ARF3 and its colocalization with the
acetylated histone H3, an index of increased transcription, in
HRG-treated cells (data not shown). In summary, our ¢nd-
ings have clearly demonstrated for the ¢rst time a potential
Fig. 3. HRG redistribution of ARF3 in breast cancer cells. A^C: MCF-7 cells were transfected with HA-tagged ARF3, serum-starved for 24 h,
then treated with HRG for 0 (A), 1 (B) or 16 h (C) and the localization of HA-ARF3 (red) and actin (green) was visualized using immuno-
staining and confocal microscopy (40U magni¢cation). Pixel intensity and immuno£uorescent colocalization along the indicated lines were
quantitated and are shown on the graphs below. D^F: MCF-7 cells were transfected with HA-ARF3, serum-starved for 24 h and then treated
with 1 nM HRG for 0 (D), 30 (E) or 60 (F) min. Immuno£uorescence and confocal microscopy showed the rapid relocalization of ARF3
(green), ¢rst to the cell membrane (E) and then to the nucleus (F). Acetylated histone H3 (red) and ARF3 colocalized (yellow) to speci¢c spots
around the nucleoli after 60 min of HRG treatment (F). Blue, nuclear counter stain.
FEBS 26284 19-7-02 Cyaan Magenta Geel Zwart
F. Li et al./FEBS Letters 524 (2002) 49^5352
role of ARF3 in the action of a physiologically relevant
growth factor, HRG, in the mammary gland. In addition,
we provide new evidence of a role for growth factor-initiated
signals in the redistribution of ARF3 to the nucleus in re-
sponse to an extracellular signal.
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Fig. 4. ARF3 expression in mammary epithelial cells. A: ARF3
protein expression in breast cancer cells as determined by Western
blot. B: ARF3 protein expression in multiple mouse organs.
C: ARF3 protein expression during mammary gland development.
V, virgin day 21; P, pregnancy days 15 and 18; L, lactation days 2
and 8; PW, post-weaning days 1 and 7. For each experiment, vincu-
lin protein was used as a loading control.
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